NCT05801133 is a Phase 2 clinical trial of Pirfenidone in Lung Cancer, sponsored by Hubei Cancer Hospital.

Who is sponsoring NCT05801133?

NCT05801133 is sponsored by Hubei Cancer Hospital.

What drugs are being tested in NCT05801133?

Interventions in NCT05801133: Pirfenidone.

What condition does NCT05801133 study?

NCT05801133 studies Lung Cancer.

Is NCT05801133 still recruiting?

NCT05801133 is currently status unknown. Last updated 15 March 2024.

Last reviewed 2024-03-15 · How we verify

NCT05801133

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pifenidone Prophylactic Therapy for Radiation Lung Injury in Patients Who Have Previously Received Immune Checkpoint Inhibitors

Status unknown Phase 2 Last updated 15 March 2024

What this trial tests

Phase 2 trial testing Pirfenidone in Lung Cancer in 41 participants. Status unknown.

Timeline

31 March 2023

Primary endpoint
31 March 2025

1 September 2025

Quick facts

Lead sponsor	Hubei Cancer Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	41
Start date	31 March 2023
Primary completion	31 March 2025
Estimated completion	1 September 2025
Sites	1 location across China

Drugs / interventions tested

Pirfenidone — full drug profile →

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

Hubei Cancer Hospital

Who can join

18 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with advanced lung cancer who have previously received immunocheckpoint inhibitor therapy, undergone chest radiation therapy again have developed radiation induced lung injury. Pirfenidone has anti-inflammatory and anti fibrosis effects. This study is intended to evaluate the effectiveness of pirfenidone combined with radiotherapy in the prevention of radiation pneumonitis.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Unravelling the Mysteries of the Sonic Hedgehog Pathway in Cancer Stem Cells: Activity, Crosstalk and Regulation.
Berrino C, Omar A. · · 2024 · cited 12× · PMID 38920995 · DOI 10.3390/cimb46060323
Use of pirfenidone in fibrotic interstitial lung diseases and beyond: a review.
Han M, Liu Q, Ji Z, Jin L, et al · · 2024 · cited 5× · PMID 39165369 · DOI 10.3389/fmed.2024.1411279
Radiomitigators: Breakthroughs in Post-Radiation Recovery.
Obrador E, Estrela JM, López-Blanch R, Moreno-Murciano P, et al · · 2026 · PMID 41897526 · DOI 10.3390/antiox15030381
Ionizing radiation: molecular mechanisms, biological effects, and therapeutic targets.
Wei W, Ren Y, Lan J, Yi J, et al · · 2026 · PMID 41507636 · DOI 10.1186/s43556-025-00358-4

Verify or expand the search:

Other trials of Pirfenidone

Trials testing the same drug.

NCT06241560 — A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in · Phase 2 · recruiting
NCT07082842 — Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF · Phase 3 · not yet recruiting
NCT07015398 — A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in · Phase 1 · completed
NCT06485635 — Real-life-persistence to Antifibrotic Treatments · completed
NCT06484153 — Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcin · Phase 1, PHASE2 · not yet recruiting

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Hubei Cancer Hospital trials

Trials by the same sponsor.

NCT07188857 — Study on the Relationship Between Opioid Drugs and the Therapeutic Efficacy of Immunotherapy · not yet recruiting
NCT06402435 — SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer · Phase 2 · recruiting
NCT06401005 — SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC) · Phase 2 · recruiting
NCT06712524 — Effect of Different Surgical Approaches of Granulomatous Mastitis · NA · recruiting
NCT06714084 — CNCMT：a Multi-center, Prospective, Single-arm Study · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05801133 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hubei Cancer Hospital
Last refreshed: 15 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05801133.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing